A landscape of driver mutations in melanoma

Hodis, Eran, Watson, Ian R., Kryukov, Gregory V., Arold, Stefan T., Imielinski, Marcin, Theurillat, Jean-Philippe, Nickerson, Elizabeth, Auclair, Daniel +32 more·2012·Cell
DOI 10.1016/j.cell.2012.06.024

Cited by (1,006)

Items 101–200 of 1,006

  1. RAS and RHO Families of GTPases Directly Regulate Distinct Phosphoinositide 3-Kinase Isoforms
    Ralph Fritsch, Inge de Krijger, Kornelia Fritsch, Roger George, Beth Reason, Madhu S Kumar, Markus E. Diefenbacher, Gordon Stamp, Julian Downward · 2013 · Cell
  2. WT1 Recruits TET2 to Regulate Its Target Gene Expression and Suppress Leukemia Cell Proliferation
    Yiping Wang, Mengtao Xiao, Xiufei Chen, Leilei Chen, Yanping Xu, Lei Lv, Pu Wang, Hui Yang, Shenghong Ma, Huaipeng Lin et al. · 2015 · Molecular Cell
  3. The NF1 somatic mutational landscape in sporadic human cancers
    Charlotte Philpott, Hannah Tovell, Ian M. Frayling, D.N. Cooper, Meena Upadhyaya · 2017 · Human Genomics
  4. Vulnerabilities of mutant SWI/SNF complexes in cancer
    K. Helming, Xiao-Feng Wang, C. Roberts · 2014 · Cancer Cell
  5. Deep sequencing of uveal melanoma identifies a recurrent mutation in PLCB4
    Peter A. Johansson, Lauren G. Aoude, Karin Wadt, William J.H. Glasson, Sunil Warrier, Alex William Hewitt, Jens Folke Kiilgaard, Steffen Heegaard, Tim Isaacs, Maria Franchina et al. · 2015 · Oncotarget
  6. A comprehensive review of protein kinase inhibitors for cancer therapy
    Radhamani Kannaiyan, Daruka Mahadevan · 2018 · Expert Review of Anticancer Therapy
  7. Mechanisms of resistance to BRAF and MEK inhibitors and clinical update of US Food and Drug Administration-approved targeted therapy in advanced melanoma
    Kakadia, Sunilkumar, Yarlagadda, Naveen, Awad, Ramez, Kundranda, Madappa, Niu, Jiaxin, Naraev, Boris, Mina, Lida, Dragovich, Tomislav, Gimbel, Mark, Mahmoud, Fade · 2018 · OncoTargets and Therapy
  8. Genetic and Clonal Dissection of Murine Small Cell Lung Carcinoma Progression by Genome Sequencing
    David G. McFadden, Thales Y. Papagiannakopoulos, Amaro N Taylor-Weiner, Chip Stewart, Scott L. Carter, Kristian Cibulskis, Arjun J. Bhutkar, Aaron McKenna, Alison L. Dooley, Amanda N. Vernon et al. · 2014 · Cell
  9. Marked for death: Targeting epigenetic changes in cancer
    Pfister, Sophia Xiao, Ashworth, Alan · 2017 · Nature Reviews Drug Discovery
  10. Mutational Signature of Aristolochic Acid Exposure as Revealed by Whole-Exome Sequencing
    Margaret L. Hoang, Chung‐Hsin Chen, Viktoriya S. Sidorenko, Jian He, Kathleen G. Dickman, Byeong Hwa Yun, Masaaki Moriya, Noushin Niknafs, Christopher Blair Douville, Rachel Karchin et al. · 2013 · Science Translational Medicine
  11. Exome sequencing of desmoplastic melanoma identifies recurrent NFKBIE promoter mutations and diverse activating mutations in the MAPK pathway
    Alan Hunter Shain, M Garrido, Thomas Botton, Eric Talevich, Iwei Yeh, Zack Sanborn, Jongsuk Chung, Nicholas J. Wang, Hojabr Kakavand, Graham J. Mann et al. · 2015 · Nature Genetics
  12. Signaling through cyclin D-dependent kinases
    Yoojin Choi, Lars Anders · 2013 · Oncogene
  13. Rho GTPase signaling in cancer progression and dissemination
    Eva Crosas‐Molist, Rémi Samain, Leonie Kohlhammer, José Luis Orgaz, Samantha L. George, Óscar Maiques, Jaume Barcelo, Victoria Sanz‐Moreno · 2021 · Physiological Reviews
  14. Evaluating the analytical validity of circulating tumor DNA sequencing assays for precision oncology
    Ira W. Deveson, Binsheng Gong, Kevin Lai, Jennifer S. LoCoco, Todd Richmond, Jeoffrey J. Schageman, Zhihong Zhang, Natalia Novoradovskaya, James C. Willey, Wendell D. Jones et al. · 2021 · Nature Biotechnology
  15. The Angiosarcoma Project: enabling genomic and clinical discoveries in a rare cancer through patient-partnered research
    Corrie Painter, Esha Jain, Brett N. Tomson, Michael Dunphy, Rachel E. Stoddard, Beena S. Thomas, Alyssa L. Damon, Shahrayz Shah, Dewey Kim, Jorge Gómez Tejeda Zañudo et al. · 2020 · Nature Medicine
  16. Melanocortin 1 Receptor: Structure, Function, and Regulation
    Erin M. Wolf Horrell, Mary Catherine Boulanger, John August D'Orazio · 2016 · Frontiers in Genetics
  17. The Cell-Cycle Regulator CDK4: An Emerging Therapeutic Target in Melanoma
    Karen E. Sheppard, Grant A. McArthur · 2013 · Clinical Cancer Research
  18. Ultraviolet Radiations: Skin Defense-Damage Mechanism
    Dheeraj Mohania, Shikha Rangra Chandel, Parveen Kumar, Vivek Verma, Kumar Digvijay, Deepika Tripathi, Khushboo Choudhury, Sandeep Kumar Mitten, Dilip Shah · 2017 · Advances in experimental medicine and biology
  19. The emerging roles of ARID1A in tumor suppression
    Ren‐Chin Wu, Tian‐Li Wang, Ie‐Ming Shih · 2014 · Cancer Biology & Therapy
  20. Elucidating Distinct Roles for <i>NF1</i> in Melanomagenesis
    Maertens, Ophélia, Johnson, Bryan, Hollstein, Pablo, Frederick, Dennie T., Cooper, Zachary A., Messiaen, Ludwine, Bronson, Roderick T., McMahon, Martin, Granter, Scott, Flaherty, Keith et al. · 2013 · Cancer Discovery
  21. Resistant mechanisms to BRAF inhibitors in melanoma
    José Luís Manzano, Laura Layos, Cristina Bugés, María de los Llanos Gil, Laia Vilà, Eva Martinez‐Balibrea, Anna Martínez‐Cardús · 2016 · Annals of Translational Medicine
  22. TERT Promoter Mutation Status as an Independent Prognostic Factor in Cutaneous Melanoma
    Klaus Griewank, Rajmohan Murali, Joan Anton Puig‐Butillé, Bastian Schilling, Elisabeth Livingstone, Míriam Potrony, Cristina Carrera, Tobias T. Schimming, Inga Möller, Marion Schwamborn et al. · 2014 · JNCI Journal of the National Cancer Institute
  23. Acquired IFNγ resistance impairs anti-tumor immunity and gives rise to T-cell-resistant melanoma lesions
    Antje Sucker, Fang Zhao, Natalia Pieper, Christina Heeke, Raffaela Maltaner, Nadine Stadtler, Birgit Real, Nicola Bielefeld, Sebastian Howe, Benjamin Weide et al. · 2017 · Nature Communications
  24. Ultraviolet radiation accelerates BRAF-driven melanomagenesis by targeting TP53
    Viros, Amaya, Sanchez-Laorden, Berta, Pedersen, Malin, Furney, Simon J., Rae, Joel, Hogan, Kate, Ejiama, Sarah, Girotti, Maria Romina, Cook, Martin, Dhomen, Nathalie et al. · 2014 · Nature
  25. Melanocytic nevi and melanoma: unraveling a complex relationship
    William Damsky, Marcus Bosenberg · 2017 · Oncogene
  26. Ribociclib (LEE011): mechanism of action and clinical impact of this selective cyclin-dependent kinase 4/6 inhibitor in various solid tumors
    Tripathy, Debu, Bardia, Aditya, Sellers, William R. · 2017 · Clinical Cancer Research
  27. Somatic TP53 Mutations in the Era of Genome Sequencing
    Pierre L. Hainaut, Gerd P. Pfeifer · 2016 · Cold Spring Harbor Perspectives in Medicine
  28. Targeting Oncogenic BRAF: Past, Present, and Future
    Aubhishek Zaman, Wei Wu, Trever Grant Bivona · 2019 · Cancers
  29. Residual Complexes Containing SMARCA2 (BRM) Underlie the Oncogenic Drive of SMARCA4 (BRG1) Mutation
    B. Wilson, K. Helming, Xiao-Feng Wang, Youngha Kim, F. Vazquez, Zainab Jagani, W. Hahn, C. Roberts · 2014 · Molecular and Cellular Biology
  30. PRC2 mediated H3K27 methylations in cellular identity and cancer
    Eric Conway, Evan Healy, Adrian P. Bracken · 2015 · Current Opinion in Cell Biology
  31. TERT promoter mutations in cancer development
    Heidenreich, Barbara, Rachakonda, P Sivaramakrishna, Hemminki, Kari, Kumar, Rajiv · 2014 · Current Opinion in Genetics &amp; Development
  32. BRD4 Sustains Melanoma Proliferation and Represents a New Target for Epigenetic Therapy
    Miguel F. Segura, Bárbara Fontanals-Cirera, Avital Gaziel‐Sovran, María V. Guijarro, Douglas Hanniford, Guangtao Zhang, Pilar González‐Gómez, Marta Morante, Luz Jubierre, Weijia Zhang et al. · 2013 · Cancer Research
  33. Understanding the Molecular Genetics of Basal Cell Carcinoma
    Pellegrini, Cristina, Maturo, Maria, Di Nardo, Lucia, Ciciarelli, Valeria, Gutiérrez García-Rodrigo, Carlota, Fargnoli, Maria · 2017 · International Journal of Molecular Sciences
  34. Retromer and sorting nexins in endosomal sorting
    Matthew Gallon, Peter J. Cullen · 2015 · Biochemical Society Transactions
  35. Mechanisms of UV-induced mutations and skin cancer
    Pfeifer, Gerd P. · 2020 · Genome Instability &amp; Disease
  36. Application of Sequencing, Liquid Biopsies, and Patient-Derived Xenografts for Personalized Medicine in Melanoma
    María Romina Girotti, Gabriela Gremel, Rebecca J. Lee, Elena Galvani, Dominic G. Rothwell, Amaya Virós, Amit Kumar Mandal, Kok Haw Jonathan Lim, Grazia Saturno, Simon J. Furney et al. · 2015 · Cancer Discovery
  37. Preclinical and clinical development of neoantigen vaccines
    L. Li, Simon Peter Goedegebuure, William E. Gillanders · 2017 · Annals of Oncology
  38. Pre-clinical modeling of cutaneous melanoma
    Vito W. Rebecca, Rajasekharan Somasundaram, Meenhard Herlyn · 2020 · Nature Communications
  39. MITF and c-Jun antagonism interconnects melanoma dedifferentiation with pro-inflammatory cytokine responsiveness and myeloid cell recruitment
    Stefanie Riesenberg, Angela Groetchen, Robert Siddaway, Tobias Bald, Julia Reinhardt, Denise Smorra, Judith D. Sirokay, Marcel Renn, Bengt Phung, Pia Aymans et al. · 2015 · Nature Communications
  40. Clustered Mutation Signatures Reveal that Error-Prone DNA Repair Targets Mutations to Active Genes
    Supek, Fran, Lehner, Ben · 2017 · Cell
  41. Molecular Pathways: SWI/SNF (BAF) Complexes Are Frequently Mutated in Cancer—Mechanisms and Potential Therapeutic Insights
    Xiaofeng Wang, Jeffrey R. Haswell, Charles W.M. Roberts · 2013 · Clinical Cancer Research
  42. Mutational Landscape of Basal Cell Carcinomas by Whole-Exome Sequencing
    Shyam S. Jayaraman, David J. Rayhan, Salar Hazany, Michael S. Kolodney · 2013 · Journal of Investigative Dermatology
  43. The NF1 gene in tumor syndromes and melanoma
    Maija H. Kiuru, Klaus Johannes BUSAM · 2017 · Laboratory Investigation
  44. PAK signaling in cancer
    Diana Z. Ye, Jeffrey M. Field · 2012 · Cellular Logistics
  45. Genomic and Transcriptomic Analysis Reveals Incremental Disruption of Key Signaling Pathways during Melanoma Evolution
    Alan Hunter Shain, Nancy M. Joseph, Richard Yu, Jamal K. Benhamida, Shanshan Liu, Tarl W. Prow, Beth S. Ruben, Jeffrey P. North, Laura Beth Pincus, Iwei Yeh et al. · 2018 · Cancer Cell
  46. The mutational landscape of mucosal melanoma
    Kelsey W. Nassar, Aik Choon Tan · 2019 · Seminars in Cancer Biology
  47. Roads to melanoma: Key pathways and emerging players in melanoma progression and oncogenic signaling
    Jasmina Paluncic, Žaklina Kovačević, Patric J. Jansson, Danuta S. Kalinowski, Angelika M. Merlot, Michael Huang, Hiu Chuen Lok, Sumit Sahni, Darius J.R. Lane, Des Raymond Richardson · 2016 · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research
  48. Mutation-Specific RAS Oncogenicity Explains NRAS Codon 61 Selection in Melanoma
    Christin Elizabeth Burd, Wenjin Liu, Minh V. Huynh, Meriam A. Waqas, James E. Gillahan, Kelly S. Clark, Kailing Fu, Brit L. Martin, William R. Jeck, George P. Souroullas et al. · 2014 · Cancer Discovery
  49. Pathways and therapeutic targets in melanoma
    Emma Shtivelman, Michael A. Davies, Patrick Hwu, James Chih-Hsin Yang, Michal Lotem, Moshe Oren, Keith T. Flaherty, David E. Fisher · 2014 · Oncotarget
  50. The Spatial Landscape of Progression and Immunoediting in Primary Melanoma at Single-Cell Resolution
    Ajit J. Nirmal, Zoltan Maliga, Tuulia Vallius, Brian Quattrochi, Alyce A. Chen, Connor A. Jacobson, Roxanne J. Pelletier, Clarence Yapp, Raquel Arias-Camison, Yu‐An Chen et al. · 2022 · Cancer Discovery
  51. Phenotype Switching: Tumor Cell Plasticity as a Resistance Mechanism and Target for Therapy
    Kemper, Kristel, de Goeje, Pauline L., Peeper, Daniel S., van Amerongen, Renée · 2014 · Cancer Research
  52. Circulating tumor DNA analysis as a real-time method for monitoring tumor burden in melanoma patients undergoing treatment with immune checkpoint blockade
    Evan J. Lipson, Victor E. Velculescu, Theresa S. Pritchard, Mark Sausen, Drew M. Pardoll, Suzanne Louise Topalian, Luis Alberto Diaz · 2014 · Journal for ImmunoTherapy of Cancer
  53. Role of the Polycomb Repressive Complex 2 (PRC2) in Transcriptional Regulation and Cancer
    Anne Laugesen, Jonas Westergaard Højfeldt, Kristian Helin · 2016 · Cold Spring Harbor Perspectives in Medicine
  54. Melanoma subtypes demonstrate distinct PD-L1 expression profiles
    Genevieve J. Kaunitz, Tricia R. Cottrell, Mohammed T. Lilo, Valliammai Muthappan, Jessica Esandrio, Sneha Berry, Haiying Xu, Aleksandra Ogurtsova, Robert A. Anders, Alexander H. Fischer et al. · 2017 · Laboratory Investigation
  55. An oncogenic Ezh2 mutation induces tumors through global redistribution of histone 3 lysine 27 trimethylation
    Souroullas, George P, Jeck, William R, Parker, Joel S, Simon, Jeremy M, Liu, Jie-Yu, Paulk, Joshiawa, Xiong, Jessie, Clark, Kelly S, Fedoriw, Yuri, Qi, Jun et al. · 2016 · Nature Medicine
  56. G quadruplexes are genomewide targets of transcriptional helicases XPB and XPD
    Lucas T. Graybuck, Aarthy C. Vallur, Johanna Eddy, Nancy Maizels · 2014 · Nature Chemical Biology
  57. Cancer gene mutation frequencies for the U.S. population
    Gaurav Mendiratta, Eugene Ke, Meraj Aziz, David Liarakos, Melinda M. Tong, Edward C. Stites · 2021 · Nature Communications
  58. A PGC1α-mediated transcriptional axis suppresses melanoma metastasis
    Chi Luo, Ji-Hong Lim, Yoonjin Lee, Scott R. Granter, Ajith Thomas, Francisca Vázquez, Hans R. Widlund, Pere Puigserver · 2016 · Nature
  59. Cancer: Evolution Within a Lifetime
    Marco Gerlinger, Nicholas McGranahan, Sally M. Dewhurst, Rebecca A. Burrell, Ian P.M. Tomlinson, Charles Swanton · 2014 · Annual Review of Genetics
  60. Molecular Profiling of Patient-Matched Brain and Extracranial Melanoma Metastases Implicates the PI3K Pathway as a Therapeutic Target
    Guo Chen, Nitin Chakravarti, Kimberly Aardalen, Alexander J. Lazar, Michael T. Tetzlaff, Bradley Stephen Wubbenhorst, Sang-Bae Kim, Scott Kopetz, Alicia A. Ledoux, Y.N. Vashisht Gopal et al. · 2014 · Clinical Cancer Research
  61. Prognosis of Mucosal, Uveal, Acral, Nonacral Cutaneous, and Unknown Primary Melanoma From the Time of First Metastasis
    Deborah Kuk, Alexander Noor Shoushtari, Christopher Andrew Barker, Katherine S. Panageas, Rodrigo Ramella Munhoz, Parisa Momtaz, Charlotte Eielson Ariyan, Mary Sue Brady, Daniel G. Coit, Kita Bogatch et al. · 2016 · The Oncologist
  62. Immune-suppressive properties of the tumor microenvironment
    Jürgen Christian Becker, Mads Hald Andersen, David Schrama, Per thor Straten · 2013 · Cancer Immunology Immunotherapy
  63. CDK 4/6 Inhibitors as Single Agent in Advanced Solid Tumors
    Francesco Schettini, Irene De Santo, Carmen Giusy Rea, Pietro De Placido, Luigi Formisano, Mario Giuliano, Grazia Arpino, Michelino De Laurentiis, Fabio Puglisi, Sabino De Placido et al. · 2018 · Frontiers in Oncology
  64. The journey from melanocytes to melanoma
    Patricia P. Centeno, Valeria Pavet, Richard Marais · 2023 · Nature reviews. Cancer
  65. Multiomic Analysis of the UV-Induced DNA Damage Response
    Stefan Boeing, Laura M. Williamson, Vesela Encheva, Ilaria Gori, Rebecca E. Saunders, Rachael Instrell, Ozan Aygün, Marta Rodríguez‐Martínez, Juston C. Weems, Gavin P. Kelly et al. · 2016 · Cell Reports
  66. Targeting oncogenic Raf protein-serine/threonine kinases in human cancers
    Robert Jr. Roskoski · 2018 · Pharmacological Research
  67. Activation of tumor suppressor protein PP2A inhibits KRAS-driven tumor growth
    Sangodkar, Jaya, Perl, Abbey, Tohme, Rita, Kiselar, Janna, Kastrinsky, David B., Zaware, Nilesh, Izadmehr, Sudeh, Mazhar, Sahar, Wiredja, Danica D., O’Connor, Caitlin M. et al. · 2017 · Journal of Clinical Investigation
  68. Tumor Genetic Analyses of Patients with Metastatic Melanoma Treated with the BRAF Inhibitor Dabrafenib (GSK2118436)
    Katherine L. Nathanson, Anne‐Marie Martin, Bradley Stephen Wubbenhorst, Joel D. Greshock, Richard Letrero, Kurt P D'Andrea, Steven J O'Day, Jeffrey R. Infante, Gerald Steven Falchook, Hendrik‐Tobias Arkenau et al. · 2013 · Clinical Cancer Research
  69. Multi-omics analysis defines core genomic alterations in pheochromocytomas and paragangliomas
    Luis Jaime Castro‐Vega, Éric Letouzé, Nelly Burnichon, Alexandre Buffet, Pierre-Hélie Disderot, Emmanuel Khalifa, Céline Loriot, Nabila Elarouci, Aurélie Morin, Mélanie Menara et al. · 2015 · Nature Communications
  70. Genome-wide kinetics of DNA excision repair in relation to chromatin state and mutagenesis
    Sheera Adar, Jinchuan Hu, Jason D. Lieb, Aziz Sancar · 2016 · Proceedings of the National Academy of Sciences
  71. Deregulation of Rho GTPases in cancer
    Andrew P. Porter, Alexandra Papaioannou, Angeliki Malliri · 2016 · Small GTPases
  72. Metabolic strategies of melanoma cells: Mechanisms, interactions with the tumor microenvironment, and therapeutic implications
    Grant M. Fischer, Y.N. Vashisht Gopal, Jennifer Leigh McQuade, Weiyi Peng, Ralph J. DeBerardinis, Michael A. Davies · 2017 · Pigment Cell & Melanoma Research
  73. Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma
    Reuben, Alexandre, Spencer, Christine N., Prieto, Peter A., Gopalakrishnan, Vancheswaran, Reddy, Sangeetha M., Miller, John P., Mao, Xizeng, De Macedo, Mariana Petaccia, Chen, Jiong, Song, Xingzhi et al. · 2017 · npj Genomic Medicine
  74. Molecular stratification of metastatic melanoma using gene expression profiling : Prediction of survival outcome and benefit from molecular targeted therapy
    Helena Cirenajwis, Henrik Ekedahl, Martin Lauss, Katja Harbst, Ana Carneiro, Jens Enoksson, Frida Rosengren, Linda Werner Hartman, Therese Törngren, Anders Kvist et al. · 2015 · Oncotarget
  75. Mining cancer methylomes: prospects and challenges
    Clare Stirzaker, Phillippa C. Taberlay, Aaron L. Statham, Susan J. Clark · 2013 · Trends in Genetics
  76. Phylogenetic analyses of melanoma reveal complex patterns of metastatic dissemination
    Zack Sanborn, Jongsuk Chung, Elizabeth A. Purdom, Nicholas J. Wang, Hojabr Kakavand, James S. Wilmott, Timothy M. Butler, John F. Thompson, Graham J. Mann, Lauren Elaine Haydu et al. · 2015 · Proceedings of the National Academy of Sciences
  77. Enhancer Remodeling during Adaptive Bypass to MEK Inhibition Is Attenuated by Pharmacologic Targeting of the P-TEFb Complex
    Zawistowski, Jon S., Bevill, Samantha M., Goulet, Daniel R., Stuhlmiller, Timothy J., Beltran, Adriana S., Olivares-Quintero, Jose F., Singh, Darshan, Sciaky, Noah, Parker, Joel S., Rashid, Naim U. et al. · 2017 · Cancer Discovery
  78. The genomic landscape of schwannoma
    Sameer Agnihotri, Shahrzad Jalali, Mark R Wilson, Arnavaz Danesh, Mira Li, George Klironomos, Jonathan R. Krieger, Alireza Mansouri, Osaama H. Khan, Yasin Mamatjan et al. · 2016 · Nature Genetics
  79. Dominant-negative SMARCA4 mutants alter the accessibility landscape of tissue-unrestricted enhancers
    H. Courtney Hodges, Benjamin Z. Stanton, Kateřina Čermáková, Chiung-Ying Chang, Erik L. Miller, Jacob G. Kirkland, Wai Lim Ku, Václav Veverka, Keji Zhao, Gerald R. Crabtree · 2017 · Nature Structural & Molecular Biology
  80. The NF1 gene revisited - from bench to bedside
    Yoon Sim Yap, John Richard McPherson, Choon Kiat Ong, Steve Rozen, Bin Tean Teh, Ann S. G. Lee, David Frederick Callen · 2014 · Oncotarget
  81. Telomerase reverse transcriptase promoter mutations in primary cutaneous melanoma
    Barbara Heidenreich, Eduardo Nagore, P. Sivaramakrishna Rachakonda, Zaida García‐Casado, Celia Requena, Víctor Traves, Jürgen Christian Becker, Nadem Soufir, Kari Hemminki, Rajiv Kumar · 2014 · Nature Communications
  82. Targeting histone lysine methylation in cancer
    John P. McGrath, Patrick Trojer · 2015 · Pharmacology & Therapeutics
  83. Targeting the ERK Signaling Pathway in Melanoma
    Paola Savoia, Paolo Fava, Filippo Casoni, Ottavio Cremona · 2019 · International Journal of Molecular Sciences
  84. <scp>MC</scp>1R, the c<scp>AMP</scp> pathway, and the response to solar <scp>UV</scp>: extending the horizon beyond pigmentation
    García‐Borrón, Jose C., Abdel‐Malek, Zalfa, Jiménez‐Cervantes, Celia · 2014 · Pigment Cell &amp; Melanoma Research
  85. The Genomic Landscape of Childhood and Adolescent Melanoma
    Charles Lu, Jinghui Zhang, Panduka Nagahawatte, John B. Easton, Seungjae Lee, Zhifa Liu, Li Ding, Matthew A. Wyczalkowski, Marcus L Valentine, Fariba Navid et al. · 2014 · Journal of Investigative Dermatology
  86. State of the science on prevention and screening to reduce melanoma incidence and mortality: The time is now
    Mary K. Tripp, Meg Watson, Sophie J. Balk, Susan M. Swetter, Jeffrey E. Gershenwald · 2016 · CA A Cancer Journal for Clinicians
  87. SWI/SNF chromatin remodeling complexes and cancer
    Jaclyn A. Biegel, Tracy Busse, Bernard E. Weissman · 2014 · American Journal of Medical Genetics Part C Seminars in Medical Genetics
  88. RAC1 P29S is a spontaneously activating cancer-associated GTPase
    Matthew J. Davis, Byung Hak Ha, Edna C. Holman, Ruth Halaban, Joseph Schlessinger, Titus J. Boggon · 2013 · Proceedings of the National Academy of Sciences
  89. Melanoma: What do all the mutations mean?
    Elizabeth J. Davis, Douglas Buckner Johnson, Jeffrey Alan Sosman, Sunandana Chandra · 2018 · Cancer
  90. The World of Melanoma: Epidemiologic, Genetic, and Anatomic Differences of Melanoma Across the Globe
    Florentia Dimitriou, Regina Krattinger, Egle Ramelyte, Marjam Jeanette Barysch, Sara Micaletto, Reinhard Dummer, Simone M. Goldinger · 2018 · Current Oncology Reports
  91. Predicting enhancer‐promoter interaction from genomic sequence with deep neural networks
    Shashank Kumar Singh, Yang Yang, Barnabás Póczos, Jian Ma · 2019 · Quantitative Biology
  92. High-throughput identification of antigen-specific TCRs by TCR gene capture
    Carsten Linnemann, Bianca Heemskerk, Pia Kvistborg, Roelof J.C. Kluin, Dmitriy A. Bolotin, Xiaojing Tina Chen, Kaspar Bresser, Marja Nieuwland, Remko Schotte, Samira Michels et al. · 2013 · Nature Medicine
  93. Rho GTPases modulate malignant transformation of tumor cells
    José Luis Orgaz, Cecilia Herráiz, Victoria Sanz‐Moreno · 2014 · Small GTPases
  94. Rac1 GTPase activates the WAVE regulatory complex through two distinct binding sites
    Chen, Baoyu, Chou, Hui-Ting, Brautigam, Chad A, Xing, Wenmin, Yang, Sheng, Henry, Lisa, Doolittle, Lynda K, Walz, Thomas, Rosen, Michael K · 2017 · eLife
  95. Broad-spectrum therapeutic suppression of metastatic melanoma through nuclear hormone receptor activation
    Pencheva, Nora, Buss, Colin G., Posada, Jessica, Merghoub, Taha, Tavazoie, Sohail F. · 2014 · Cell
  96. Genetic alterations of JAK/STAT cascade and histone modification in extranodal NK/T-cell lymphoma nasal type
    Seungbok Lee, Ha Young Park, So Young Kang, Seok Jin Kim, Jinha Hwang, Seungho Lee, Soo Heon Kwak, Kyong Soo Park, Hae Yong Yoo, Won Seog Kim et al. · 2015 · Oncotarget
  97. A Novel AKT1 Mutant Amplifies an Adaptive Melanoma Response to BRAF Inhibition
    Hubing Shi, Aayoung Hong, Xiangju Kong, Richard Chikara Koya, Chunying Song, Gatien Moriceau, Willy Hugo, Clarissa C. Yu, Charles Ng, Thinle Chodon et al. · 2013 · Cancer Discovery
  98. Current Advances in the Treatment of BRAF-Mutant Melanoma
    Hima Milan Patel, Nour Yacoub, Rosalin Mishra, Aaron White, Long Yuan, Samar Alanazi, Joan T. Garrett · 2020 · Cancers
  99. Homologous Mutation to Human BRAF V600E Is Common in Naturally Occurring Canine Bladder Cancer—Evidence for a Relevant Model System and Urine-Based Diagnostic Test
    Brennan James Decker, Heidi G. Parker, Deepika Dhawan, Erika Mijin Kwon, Eric Karlins, Brian W. Davis, Jose A. Ramos, Patty L. Bonney, Elizabeth A. McNiel, Deborah W. Knapp et al. · 2015 · Molecular Cancer Research
  100. Future perspectives in melanoma research
    Paolo A. Ascierto, Sanjiv S. Agarwala, Gerardo Botti, Alessandra Cesano, Gennaro Ciliberto, Michael A. Davies, Sandra Demaria, Reinhard Dummer, Alexander M.M. Eggermont, Soldano Ferrone et al. · 2016 · Journal of Translational Medicine